术中万古霉素不改变全关节置换术患者假体周围关节感染风险
该研究基于全国数据库,比较初次全髋/膝关节置换术患者术中加用万古霉素与未加用者的90天感染及内科并发症和5年无翻修生存率。匹配后分析显示,术中万古霉素与90天表浅手术部位感染或假体周围关节感染风险降低无关,也未增加其他不良事件风险,两组5年无翻修生存率相当。
要点
- 术中万古霉素与90天表浅手术部位感染或假体周围关节感染风险降低无关。
- 术中万古霉素未增加其他不良事件风险。
- 全髋与全膝匹配组5年无翻修生存率相当。
核心结论
- 在该队列中,术中万古霉素与90天手术部位感染或假体周围关节感染风险降低无关,也未改善5年无翻修生存率。
研究设计与样本
- 研究基于全国数据库,纳入2010年1月至2023年4月因骨关节炎行初次全髋或全膝关节置换术且当日接受头孢唑林预防的成年患者。
- 排除标准包括耐甲氧西林金黄色葡萄球菌或假体周围关节感染史、90天内既往感染、术前90天至术后3天内任何抗生素处方。
- 将加用与未加用术中万古霉素的患者按年龄、性别、Elixhauser合并症指数、体重指数大于40、II型糖尿病、胰岛素使用、吸烟状态和地理区域进行1:1匹配。
- 全髋关节置换术患者共78,778例,其中20,841例(26.5%)接受术中万古霉素,匹配后每组17,051例。
- 全膝关节置换术患者共171,274例,其中49,145例(28.7%)接受万古霉素,匹配后每组43,569例。
主要发现
- 两种手术中,术中万古霉素与90天表浅手术部位感染或假体周围关节感染的比值降低均无关。
- 术中万古霉素未增加任何其他不良事件的比值。
- 全髋关节置换术匹配组和全膝关节置换术匹配组的5年无翻修生存率相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cephalosporins are the primary prophylactic antibiotic in primary total hip and knee arthroplasty (THA and TKA). There is interest in augmenting this effect by adding intraoperative vancomycin via intrawound, intraosseous, or intravenous routes. However, low periprosthetic joint infection (PJI) rates have hindered statistical power and consensus within prior research. This study aimed to compare 90-day infectious and medical complications and 5-year revision-free survival among patients who did and did not have intraoperative vancomycin within a large, nationally representative population. METHODS: Within a national database, adult patients undergoing primary THA or TKA for osteoarthritis from January 2010 to April 2023 who received same-day cefazolin prophylaxis were identified. Exclusion criteria included methicillin-resistant Staphylococcus aureus or PJI history, prior infection within 90 days, and any antibiotic prescription within 90 days before and three days following surgery. Patients who did and did not have the addition of intraoperative vancomycin were matched (1:1) on age, sex, Elixhauser Comorbidity Index, body mass index greater than 40, type II diabetes, insulin use, smoking status, and geographic region. Among 78,778 THA patients, 20,841 (26.5%) received intraoperative vancomycin, yielding 17,051 matched patients per group. Among 171,274 TKA patients, 49,145 (28.7%) received vancomycin, yielding 43,569 matched patients per group. The 90-day complications were assessed using univariable and multivariable logistic regressions. The 5-year revision-free survival was evaluated with Kaplan-Meier analysis and log-rank testings. Significance was defined as P < 0.003, per Bonferroni correction. RESULTS: Across both procedures, intraoperative vancomycin was not associated with reduced 90-day odds of superficial surgical site infection or PJI, nor increased odds of any other adverse event. The 5-year revision-free survival was comparable between both the THA and TKA matched groups. CONCLUSIONS: In this cohort, intraoperative vancomycin was not associated with lower odds of 90-day surgical site infection or PJI, nor improved 5-year revision-free survival.
引用
- Jiang WM, Sanchez JG, Halperin SJ, et al. Intraoperative Vancomycin Does Not Change Periprosthetic Joint Infection Risk in Patients Undergoing Total Joint Arthroplasty. J Arthroplasty. 2026. PMID: 41544893. doi:10.1016/j.arth.2026.01.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。